Refix

Quick links to important sections

Refix

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Refix

Defining Refix: An Overview of the Active Agent

Property Description
Active ingredient Cefixime
Form Tablets, capsules, oral suspension
Pharmacological class Third-generation cephalosporin
Common use Elimination of bacterial infections
Origin Semi-synthetic compound

Refix is a prescription-only medicine that contains the single active substance Cefixime, which is chemically classified as a semi-synthetic beta-Lactam antibiotic. This core compound belongs to the third-generation cephalosporin pharmacological class, a key detail clinically recognized by public health authorities. Cefixime is widely noted for its structural stability and its potent, reliable activity against a wide variety of common pathogenic bacteria, distinguishing it from antibiotics in other classes. Cefixime is an established and effective oral third-generation cephalosporin for systemic treatment. This drug delivers anti-infective treatment systemically throughout the body.

What Type of Medicine is Refix and What is Its Purpose?

Refix is a bactericidal anti-infective agent designed to directly kill invading bacteria throughout the body. Its general therapeutic purpose is to effectively eliminate microbial proliferation and resolve various underlying bacterial infections. Cefixime's bactericidal activity is based on the inhibition of essential cell wall synthesis. This confirms that the medicine works by destroying the structure needed for the survival and multiplication of harmful pathogens. This targeted physiological effect ensures the rapid reduction of the microbial load, supporting recovery in common infection scenarios.

Available Forms and Composition

Refix is formulated as a single-ingredient product intended for convenient oral administration. The preparation is available as tablets and capsules, as well as an oral suspension suitable for pediatric patients or individuals who have difficulty swallowing solid medication. The availability of the suspension form, specifically tailored for ease of dosing in younger age groups, represents a differentiating factor in its use. The composition consists of the active Cefixime, typically present as its trihydrate salt, combined with necessary pharmaceutical excipients to ensure the proper absorption and stability of the therapeutic agent after consumption.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Refix?

Refix, a coagulation Factor IX product, is generally well-tolerated, but like all medications, it can cause side effects. It is important to discuss any concerns or pre-existing conditions with a healthcare provider.

Potential Side Effects

Side effects associated with Factor IX treatment can vary in frequency and severity. Patients should be aware of the following:

  • Common Reactions (may affect up to 1 in 10 patients):

    • Headache
    • Injection site reactions (pain, redness, or swelling)
    • Nausea and Vomiting
    • Flushing (a feeling of warmth or redness)
  • Serious Adverse Events (uncommon or rare):

    • Hypersensitivity and Allergic Reactions: These may include hives, rash, itching, swelling of the face, lips, tongue, or throat, chest tightness, wheezing, and difficulty breathing. Anaphylaxis is a severe form of allergic reaction and requires immediate medical attention.
    • Inhibitor Development: The body may develop neutralizing antibodies (inhibitors) against Factor IX, causing the medicine to stop working effectively and leading to a loss of bleeding control. Regular monitoring for inhibitor development is necessary.
    • Thromboembolic Events: Factor IX products carry a risk of blood clots (thrombosis) forming in the blood vessels, which can lead to serious conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE). This risk is often higher in patients with liver disease, or those with other risk factors for clotting disorders.

Safety and Contraindications

Refix is typically contraindicated in patients with a known history of a severe allergic reaction (hypersensitivity) to the product or to any of its components, including hamster proteins if the product is recombinant. Patients with a history of blood clotting issues, such as disseminated intravascular coagulation (DIC), should use Factor IX products with extreme caution. Always inform your healthcare professional about all medications, supplements, and pre-existing conditions before starting treatment.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation indicates that experience with Refix (Cefixime) overdosage does not typically present with a unique symptom profile separate from severe adverse reactions seen at high drug concentrations. The official focus is placed on the potential for severe, life-threatening outcomes affecting critical body systems.

Documented Manifestations and Serious Outcomes

Overdose may manifest as an escalation of adverse effects on the Central Nervous System (CNS), potentially leading to seizures. Other documented severe outcomes include acute renal failure and severe hypersensitivity reactions, such as anaphylaxis. Regulatory labeling also notes laboratory changes, including transient elevations in markers of kidney function (BUN and Creatinine) and liver function (SGOT and SGPT).

Emergency Actions and Management Constraints

Immediate medical attention is required if severe symptoms like seizures or signs of a severe allergic reaction occur. For patients experiencing seizures associated with the drug, official guidance mandates prompt discontinuation of the medication, with the possible use of anticonvulsant therapy.

The official prescribing information explicitly states that no specific antidote exists for Cefixime overdosage. Furthermore, the drug is not removed in significant quantities by dialysis, including hemodialysis or peritoneal dialysis, meaning management is primarily limited to general supportive measures. A key population-specific risk noted is the increased potential for seizures in patients with renal impairment if their dosage is not appropriately adjusted, leading to excessive systemic concentration.

Therapeutic Uses of Refix

What Refix Treats: Main Uses and Benefits

Refix (Cefixime) is a therapeutic option commonly used across conditions presenting with acute episodes to provide support for managing symptoms related to physical discomfort and functional strain associated with specific bacterial infections. The therapeutic intent is focused on treating the source of infection, which may assist with easing symptoms related to physical discomfort and contributes to patient recovery. The medicine is used to treat infections caused by bacteria, including those affecting the ears, throat, tonsils, urinary tract, and lungs (bronchitis).


Refix is applied across domains where additional symptomatic support is needed, specifically targeting conditions where symptoms cluster into patterns of pain, inflammation, and respiratory distress. It is commonly used for infections like bacterial otitis media, pharyngitis, acute bronchitis, uncomplicated UTIs, and more severe systemic infections such as typhoid fever. The treatment supports improved day-to-day comfort by helping to ease the overall burden of symptoms, including fever and localized discomfort. The medication is relevant for easing symptoms that interfere with daily comfort.


Quick Fact: Relief for Inflammatory States The medication is relevant for managing symptoms related to inflammatory or irritative states caused by susceptible bacteria, which may assist with easing distress during difficult episodes.

Regulatory References

  1. NIH MedlinePlus overview of Cefixime

Eligibility and Restrictions for Use

Who Can and Cannot Use Refix (Cefixime) — Official Regulatory Information

Refix is officially contraindicated and must not be used by patients with a known history of hypersensitivity to Cefixime or any other cephalosporin antibiotic. Due to documented cross-allergenicity, caution is required when prescribing Refix to individuals with a history of penicillin allergy.

Population Eligibility

Population Group Regulatory Status
Adults and Adolescents Approved for standard use.
Pediatric Patients Approved for use in children 6 months of age and older.
Infants Safety and effectiveness have not been established in infants younger than 6 months.
Severe Renal Impairment Requires mandatory dosage adjustment but is not absolutely prohibited.
Pregnancy/Lactation Use is documented as appropriate only if clearly needed; caution is advised during breastfeeding.

Eligibility is defined by official labeling, which also specifies constraints based on pre-existing conditions. Use requires caution for populations with a history of gastrointestinal disease, such as colitis. Additionally, patients with Phenylketonuria (PKU) must avoid the chewable tablet formulation due to its phenylalanine content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Refix (Cefixime) detail specific interaction patterns with other medicines and substances. These interactions are classified primarily into those that modify drug exposure and those that alter physiological parameters, with no combinations formally listed as contraindicated solely due to interaction risk.


Drug-Drug Interaction Patterns

Co-administration with Probenecid, a substance known to inhibit renal tubular secretion, is documented to result in increased Cefixime plasma concentrations (C max and AUC) and reduced clearance of the drug. This effect is a formal pharmacokinetic interaction.

A distinct, documented interaction involves concurrent use with anticoagulants, such as Warfarin and other Vitamin K antagonists. This combination is classified as a pharmacodynamic interaction because it increases the measured prothrombin time (PT), raising the risk of altered hemostasis and bleeding. Additionally, official data show that co-administration with Salicylates may result in a documented decrease of approximately 20–25% in Cefixime's peak serum concentration. Elevated levels of Carbamazepine have also been reported when co-administered with Cefixime.


Food and Population Considerations

Absorption of the drug's oral suspension form is not significantly altered by the presence of food. For the tablet and capsule forms, while the extent of absorption is not significantly affected, the time taken to reach peak concentration may be delayed. For patients with hepatic or renal impairment or poor nutritional status, the official labeling notes these as risk factors for increased prothrombin activity when Cefixime is co-administered with anticoagulants.

Mechanism of Action

Targeted Disruption of Bacterial Cell Wall Synthesis

Refix functions as a covalent, irreversible inhibitor by specifically targeting Penicillin-Binding Proteins (PBPs)—enzymes crucial for maintaining bacterial structural integrity. By neutralizing the PBP transpeptidase activity, the drug blocks the necessary cross-linking of peptidoglycan, leading to the formation of a fundamentally defective and fragile bacterial cell wall.

Catastrophic Structural Failure and Bactericidal Effect

The structural flaw in the cell wall prevents the bacterium from withstanding its high internal osmotic pressure (turgor), which is the functional consequence of the mechanism. This imbalance causes the cell to rapidly swell and rupture (lysis), resulting in the bactericidal effect and the destruction of actively multiplying bacteria. This mechanism is physiologically constrained, as its action is ineffective against non-multiplying bacteria or strains that produce beta-Lactamase enzymes that inactivate the drug.

Dosage and Administration Information

How to Use Refix: Official Administration Guidelines

Refix (Cefixime) is strictly approved for oral administration only, available as tablets, capsules, and a powder for oral suspension. The general dosing for adults is 400 mg total daily, which may be taken as a single dose or in two divided doses of 200 mg every 12 hours, depending on the infection being treated. The medication may be taken with or without food.


Dosing Patterns and Duration

Population Group Standard Regimen Course Duration Principle
Adults (General) 400 mg once daily or 200 mg every 12 hours Typically 7 to 14 days
Pediatric (6 months+) 8 mg/kg body weight total daily, in one or two doses Minimum 10 days for Streptococcus infections

Special Administration Instructions

The total treatment duration is often 7 to 14 days, but specific infections caused by Streptococcus pyogenes (e.g., tonsillitis) require a mandatory duration of at least 10 days. For those with significant kidney impairment (creatinine clearance less than 20 mL/min), the maximum dose must be reduced to 200 mg once daily. The oral suspension, once reconstituted, must be shaken well before measuring the dose and should not be substituted for tablets or capsules when treating otitis media, as this may affect medication levels in the blood. If a dose is missed, it should be taken as soon as it is remembered unless it is almost time for the next scheduled dose; the official guidance prohibits doubling the next dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Refix (Cefixime)

Evidence for use in Respiratory and Ear Infections

Clinical research, including multiple Randomized Controlled Trials (RCTs) and systematic reviews, was studied for Refix in conditions such as middle ear infections (Acute Otitis Media) and Pharyngitis/Tonsillitis (infections of the throat). These studies explored outcomes related to physical discomfort and functional imbalance that characterize acute episodes. Researchers mainly examined whether the symptoms evolved in the observed populations to meet predefined criteria for resolution (clinical outcome), and whether tests monitored the bacteriological status following treatment (bacteriological outcome).

Studies provided measurements detailing the evolution of symptoms and the changes in bacteriological status, often involving a comparative design against other established antibiotic regimens. What remains less characterized is the long-term data characterizing recurrence rates for these infections. Data for certain groups, particularly those with complex or chronic underlying issues, remain limited for drawing wide-ranging conclusions.


Evidence for use in Urinary Tract Infections (UTIs)

Refix was studied for the management of uncomplicated UTIs across several clinical trials and summarized in systematic reviews. This research explored outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort. The primary research focus was on whether the susceptible bacteria were monitored for bacteriological status and if the associated urinary symptoms met the predefined criteria for clinical outcome during the study period.

The evidence consists of consistent findings reported across several different studies. However, the applicability of older data is considered in the context of emerging regional antibiotic resistance patterns.


What is Still Uncertain About the Research

The authoritative research landscape highlights areas where data are still emerging or where evidence is limited. One key limitation is that comparative evidence is lacking for some of the most current and advanced alternative treatments. Furthermore, follow-up durations were limited across the primary trial evidence, meaning that long-term outcomes are not well characterized. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Studies help show what has been observed so far, but evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Natural history of uncomplicated urinary tract infection without antibiotics: a systematic review (Informing context for UTI management)
  2. FDA Label and Prescribing Information for Cefixime (Suprax) - Indications and Special Populations
  3. Summary of Product Characteristics (SPC) for Cefixime (EU/Global Regulatory Context)

Frequently Asked Questions (FAQ)

Common questions about Refix (FAQ)

Q: How quickly should Refix start to make a difference?

Clinical studies and official information describe that observed populations often start to experience symptomatic relief within the first few days of treatment with Cefixime. Regulatory guidance on antibiotic use emphasizes that completing the full prescribed course is important to minimize the risk of bacterial return and to support the eradication of the infection.


Q: What happens if I miss a dose of Refix?

Official prescribing information states that a missed dose should be taken as soon as the patient remembers. If it is almost time for the next scheduled dose, the missed dose should be skipped. Regulatory instructions advise against taking a double dose to make up for a missed one.


Q: Can Refix cause changes in mood or sleep?

In the official product information, specific mood changes, psychiatric reactions, or sleep disorders are not listed among the commonly or rarely reported side effects for Refix. Side effect profiles focus mainly on physical reactions like gastrointestinal issues and headaches.


Q: Can people with heart issues use Refix?

Official regulatory documents do not list general heart or cardiac conditions as an absolute contraindication for use. Contraindications are primarily related to hypersensitivity to the drug class, such as Cefixime or other cephalosporin antibiotics.


Q: Does Refix require any special monitoring or blood tests?

Cefixime, the active ingredient in Refix, is documented to potentially affect the results of certain laboratory tests, particularly those related to blood clotting (coagulation). The drug label suggests that healthcare providers and laboratory workers should be informed that a patient is taking Cefixime when undergoing coagulation tests or using blood-thinning medications.


Q: Does Refix affect birth control or fertility?

Animal studies conducted on Cefixime did not show evidence of impaired fertility. Furthermore, official product labeling does not document any specific interaction that reduces the effectiveness of hormonal birth control when taken with Refix.


Q: Is it possible to become dependent on Refix?

Official regulatory product information for Cefixime, as an antibiotic, does not list physical dependence or addiction as a known or potential risk associated with its use.


Q: Does Refix have a generic version available?

Cefixime is the name of the active pharmaceutical ingredient. Information from regulatory databases indicates that it is available as a generic drug from various manufacturers, in addition to its branded form.


Q: Will Refix cause weight gain or loss?

Changes in body weight (gain or loss) are not specified among the documented common or rare side effects reported in the official product information for Refix.


Q: Is it safe to drink a small amount of alcohol while on Refix?

The official prescribing information for Cefixime does not include a specific drug interaction warning or contraindication regarding the concurrent consumption of alcohol. The label provides information about what is known, but does not provide personal guidance.


Q: What are the most commonly reported reasons for stopping Refix?

Official data indicates that among the adverse events observed in studies, the most frequent side effects associated with treatment discontinuation are related to the digestive system. These primarily include diarrhea, loose stools, nausea, and occasional vomiting.


Q: Why do some users report feeling tired when they first start Refix?

While tiredness or fatigue is not listed as one of the most common side effects in the official prescribing information, a general feeling of weakness is a minor adverse reaction that has been noted during Cefixime use.


Q: Why is the official dosage of Refix what it is?

The official dosage and administration instructions are determined by extensive clinical trial evidence and pharmacokinetic data. This information establishes the drug concentration level required to reliably treat target bacterial infections while maintaining a favorable risk profile.


Q: Can Refix interact with caffeine or energy drinks?

The official product information primarily lists interactions with certain prescription drugs and salicylates. No specific documented interactions between Cefixime and substances like caffeine or common energy drinks are detailed in the official regulatory documents.


Q: Is there any data on Refix use in pediatric patients?

Yes, regulatory data confirms that the safety and effectiveness of Refix have been established for pediatric patients aged six months and older. The recommended administration for this population is based on body weight, utilizing specific liquid suspension forms.


Q: What should I do if the expected effect of Refix doesn't seem to happen?

If symptoms do not begin to improve or if they seem to worsen, the patient information advises seeking further evaluation from a healthcare provider. Discontinuing the medication without professional medical guidance is generally advised against.


Q: Do studies suggest Refix is better taken in the morning or evening?

The official regulatory labeling states that Refix can be taken as a single daily dose or in two divided doses every 12 hours. Studies and documentation focus on the necessity of consistent daily timing rather than recommending a specific time of day (morning versus evening) for optimal results.


Q: Can Refix cause problems with vision?

Official prescribing information for Cefixime does not list problems with vision, such as temporary or permanent visual impairment, among the commonly or rarely reported adverse effects.


Q: Is Refix safe for use during pregnancy or breastfeeding, according to official sources?

Regulatory information describes that use during pregnancy is considered only when the potential benefit is assessed to clearly outweigh the potential risk. Because Cefixime is known to be excreted into human breast milk, the decision must be made to either stop nursing or stop using the drug.


Q: Why is Refix sometimes described as a 'novel' treatment?

Refix's active ingredient, Cefixime, is officially classified as a semi-synthetic beta-lactam antibiotic and a third-generation cephalosporin. The distinction as a third-generation cephalosporin places it among later-developed antibiotics compared to older classes.


Q: How long does Refix stay in the body after the last dose?

The pharmacokinetic data for Refix indicates that the serum half-life in healthy individuals is approximately 3 to 4 hours. The half-life is the time required for the amount of the drug in the bloodstream to be reduced by half. Elimination of the drug occurs primarily through the urine.


Q: Are there different strengths of Refix, and why?

Yes, Refix (Cefixime) is available in different strengths, such as 400 mg tablets and varying concentrations for the oral suspension. This is necessary to accommodate different approved dosing regimens for adults, as well as the accurate, weight-based dosing requirements for pediatric patients.


Q: Can I stop taking Refix suddenly, or do I need to taper off?

Official regulatory guidance emphasizes the importance of continuing the medication until the full prescribed amount has been finished. Stopping the antibiotic too early is linked to the return of the infection and can contribute to the development of drug-resistant bacteria.


Q: What is the official classification of Refix (e.g., monoclonal antibody, kinase inhibitor, etc.)?

The official classification of the active ingredient, Cefixime, is as a semi-synthetic beta-lactam antibiotic. It belongs to the cephalosporin pharmacological class, which is a key detail for healthcare providers prescribing the medicine.

How should Refix be stored and disposed of?

The official regulatory requirements for storing Refix (Cefixime) vary based on the form. Tablets, capsules, and the dry powder for oral suspension must be stored at controlled room temperature, between 20 C and 25 C (68 F and 77 F). All forms must be kept in the tightly closed original container, protected from excessive moisture, light, and must not be frozen.

Once the dry powder is mixed, the liquid oral suspension is stable for only 14 days, whether stored at room temperature or refrigerated. Any unused suspension must be discarded after 14 days. All medication must be kept out of the sight and reach of children. Unused or expired Refix should not be placed in household trash or wastewater and should be disposed of via a medicine take-back program or specific at-home disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Refix found in:

A-Z Index: